|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The genotypes of XPD Asp312Asn (p=0.2493), Lys751Gln (p=0.7547) and promoter -114 (p=0.8702), were not associated with susceptibility for colorectal cancer.
|
27069143 |
2016 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The correlation between ERCC1 polymorphisms (rs11615 and rs3212986) and XPD polymorphisms (rs13181 and rs1799793) with the response rate and overall survival of cancer patients who accept neoadjuvant therapy has been extensively investigated.However, the results are inconclusive.
|
26426637 |
2015 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Xeroderma pigmentosum group D (XPD, also referred to as excision repair cross complementing gene 2, ERCC2) is one of key genes involved in nucleotide excision repair and two potentially functional polymorphisms of XPD (Asp312Asn and Lys751Gln) have been widely investigated in various cancers including prostate cancer.
|
23771356 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Numerous epidemiological studies have been conducted to investigate the association between Xeroderma pigmentosum complementation group D (XPD) Asp312Asn (rs1799793 G > A) and Lys751Gln (rs13181 A > C) polymorphisms and bladder cancer risk; however, the conclusions remain controversial.
|
24347488 |
2014 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two commonly studied single nucleotide polymorphisms (SNPs) of XPD (Lys751Gln, A>C, rs13181; Asp312Asn, G>A, rs1799793) are implicated in the modulation of DNA repair capacity, thus related to the responses to platinum-based chemotherapy.
|
24260311 |
2013 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our investigations demonstrate that XPD Asn312Asp SNP not the Gln751Lys SNP, might poorly increase PCa risk in Asians and Africans, moreover, this SNPs may associate with the tumor stage of PCa.
|
23028604 |
2012 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
XPD Asp312Asn (rs1799793) of Han ethnic was associated with a borderline decrease of ESCC (OR: 0.362, 95% CI: 0.145-0.906), however, it was associated with ESCC risk in Uygur ethnic (OR: 2.403, 95% CI: 1.087-5.310).
|
21553048 |
2012 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
A statistically significant finding could also be seen in high quality subgroup, small-and-moderate sample size subgroup, articles published after 2007, or PCR-RFLP genotyping subgroup for XPD Asp312Asn polymorphism.
|
23028453 |
2012 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
No clear association between XPD Asp312Asn or XPD Lys751Gln gene polymorphisms and lung cancer was found.
|
15615908 |
2005 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated the genetic basis for these findings by analysing the Asp312Asn and Lys751Gln polymorphisms of the XPD (ERCC2) DNA repair gene in the same subjects.
|
14735199 |
2004 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
To determine whether the XRCC1 (codon Arg399Gln) and XPD (codon Asp312Asn and codon Lys751Gln) polymorphisms are associated with prostate cancer susceptibility, we genotyped these polymorphisms in a primarily Caucasian sample of 506 sibships (n = 1,117) ascertained through a brother with prostate cancer.
|
14744728 |
2004 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
|
12844488 |
2003 |